top of page
OA Hero 1 advocacy v4 -Skin.jpg

Non-Melanoma Skin Cancer

Theranostics Beyond Traditional Skin Cancer Care

Theranostic approaches are increasingly being explored and utilised in the management of selected non-melanoma skin cancers.

Innovations in imaging, targeted therapies and radionuclide treatments continue to expand treatment possibilities.

Treatments

Appropriate treatment options vary depending on:

  • Cancer type

  • Disease stage

  • Location

  • Patient circumstances

Research

Research is ongoing into:

  • Novel radionuclide therapies

  • Personalised treatment approaches

  • Improved patient outcomes

Patient Guide

Patients should discuss available treatment options with their dermatologist, radiation oncologist or other treating specialist.

Learn More

Nuclear medicine is also contributing to new approaches for treating selected non-melanoma skin cancers (NMSC). In Australia, Rhenium-188 brachytherapy provides a localised radionuclide treatment in which beta radiation is delivered directly to the affected skin lesion.

Unlike established theranostic pathways such as PSMA-targeted treatment for prostate cancer or PRRT for neuroendocrine tumours, Rhenium-188 skin therapy does not rely on molecular imaging to identify a corresponding biological target before treatment. It is therefore more accurately described as a targeted radionuclide therapy rather than a classical theranostic approach.

Its inclusion within the broader theranostics conversation reflects the expanding role of radiopharmaceutical science and targeted radionuclide therapies in precision cancer care.

Frequently Asked Questions

Continue Exploring

Frequently Asked Questions

Explore answers to some of the most common questions about theranostics, precision medicine and targeted cancer care.​

​

Discover Now

Stay Connected

Join our community to receive educational resources, industry updates, event invitations and the latest developments in theranostics.​

​

Joun Our Community

Medical Disclaimer
The information provided on this website is intended for educational purposes only and should not be considered medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals who can consider individual circumstances and clinical needs.

Oncothera ICON white

Oncothera Advocacy is the Voice for Theranostics

Support Us

Quick Links

Small Print

Privacy Policy

Disclaimer

​​

Site developed by
 Showoff Group.

ACNC registration logo

Oncothera Advocacy is a Registered Charity with the Australian Charities and Not–for–profit Commission.

Acknowledgement of Country

Oncothera Advocacy acknowledges Aboriginal and Torres Strait Islander peoples as the Traditional Custodians of the lands on which we live, work and connect. We pay our respects to Elders past and present, and recognise their continuing connection to land, waters, culture and community.

Commitment to Inclusion

Oncothera Advocacy is committed to an inclusive healthcare community where everyone is treated with dignity, respect and equity. We welcome and support people of all backgrounds, cultures, identities, genders and sexual orientations, including LGBTQIA+ communities.

bottom of page